Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Malignant Lymphoma

  Free Subscription


Articles published in J Clin Oncol

Retrieve available abstracts of 90 articles:
HTML format
Text format



Single Articles


    June 2017
  1. GROMMES C, DeAngelis LM
    Primary CNS Lymphoma.
    J Clin Oncol. 2017 Jun 22:JCO2017727602. doi: 10.1200/JCO.2017.72.7602.
    PubMed     Text format     Abstract available


    May 2017
  2. STAIGER AM, Ziepert M, Horn H, Scott DW, et al
    Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group.
    J Clin Oncol. 2017 May 19:JCO2016703660. doi: 10.1200/JCO.2016.70.3660.
    PubMed     Text format     Abstract available


  3. WITZIG TE
    Maintenance Lenalidomide for Large-Cell Lymphoma: Who Really Benefits?
    J Clin Oncol. 2017 May 17:JCO2017732578. doi: 10.1200/JCO.2017.73.2578.
    PubMed     Text format    


  4. OU SI
    Further Advances in the Management of Anaplastic Lymphoma Kinase-Mutated Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2017 May 11:JCO2017731323. doi: 10.1200/JCO.2017.73.1323.
    PubMed     Text format    


  5. LANDSBURG DJ, Falkiewicz MK, Maly J, Blum KA, et al
    Outcomes of Patients With Double-Hit Lymphoma Who Achieve First Complete Remission.
    J Clin Oncol. 2017 May 5:JCO2017722157. doi: 10.1200/JCO.2017.72.2157.
    PubMed     Text format     Abstract available


  6. KIM DW, Tiseo M, Ahn MJ, Reckamp KL, et al
    Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial.
    J Clin Oncol. 2017 May 5:JCO2016715904. doi: 10.1200/JCO.2016.71.5904.
    PubMed     Text format     Abstract available


  7. LAURENT C, Baron M, Amara N, Haioun C, et al
    Impact of Expert Pathologic Review of Lymphoma Diagnosis: Study of Patients From the French Lymphopath Network.
    J Clin Oncol. 2017 May 1:JCO2016712083. doi: 10.1200/JCO.2016.71.2083.
    PubMed     Text format     Abstract available


    April 2017
  8. KAMDAR MK, Smith SM
    Extranodal Marginal Zone Lymphoma: No Longer Just a Sidekick.
    J Clin Oncol. 2017 Apr 27:JCO2017722835. doi: 10.1200/JCO.2017.72.2835.
    PubMed     Text format     Abstract available


  9. CHEN R, Zinzani PL, Fanale MA, Armand P, et al
    Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma.
    J Clin Oncol. 2017 Apr 25:JCO2016721316. doi: 10.1200/JCO.2016.72.1316.
    PubMed     Text format     Abstract available


  10. THIEBLEMONT C, Tilly H, Gomes da Silva M, Casasnovas RO, et al
    Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone.
    J Clin Oncol. 2017 Apr 20:JCO2017726984. doi: 10.1200/JCO.2017.72.6984.
    PubMed     Text format     Abstract available


  11. SASSE S, Brockelmann PJ, Goergen H, Plutschow A, et al
    Long-Term Follow-Up of Contemporary Treatment in Early-Stage Hodgkin Lymphoma: Updated Analyses of the German Hodgkin Study Group HD7, HD8, HD10, and HD11 Trials.
    J Clin Oncol. 2017 Apr 18:JCO2016709410. doi: 10.1200/JCO.2016.70.9410.
    PubMed     Text format     Abstract available


  12. MEYER RM
    Limited-Stage Hodgkin Lymphoma: Clarifying Uncertainty.
    J Clin Oncol. 2017 Apr 3:JCO2017722611. doi: 10.1200/JCO.2017.72.2611.
    PubMed     Text format    


    March 2017
  13. ZUCCA E, Conconi A, Martinelli G, Bouabdallah R, et al
    Final Results of the IELSG-19 Randomized Trial of Mucosa-Associated Lymphoid Tissue Lymphoma: Improved Event-Free and Progression-Free Survival With Rituximab Plus Chlorambucil Versus Either Chlorambucil or Rituximab Monotherapy.
    J Clin Oncol. 2017 Mar 29:JCO2016706994. doi: 10.1200/JCO.2016.70.6994.
    PubMed     Text format     Abstract available


  14. MOFFITT AB, Dave SS
    Clinical Applications of the Genomic Landscape of Aggressive Non-Hodgkin Lymphoma.
    J Clin Oncol. 2017;35:955-962.
    PubMed     Text format     Abstract available


  15. ANDRE MP, Girinsky T, Federico M, Reman O, et al
    Early Positron Emission Tomography Response-Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 Trial.
    J Clin Oncol. 2017 Mar 14:JCO2016686394. doi: 10.1200/JCO.2016.68.6394.
    PubMed     Text format     Abstract available


  16. SCOTT DW, Abrisqueta P, Wright GW, Slack GW, et al
    New Molecular Assay for the Proliferation Signature in Mantle Cell Lymphoma Applicable to Formalin-Fixed Paraffin-Embedded Biopsies.
    J Clin Oncol. 2017 Mar 14:JCO2016707901. doi: 10.1200/JCO.2016.70.7901.
    PubMed     Text format     Abstract available


  17. KOCHENDERFER JN, Somerville RP, Lu T, Shi V, et al
    Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels.
    J Clin Oncol. 2017 Mar 14:JCO2016713024. doi: 10.1200/JCO.2016.71.3024.
    PubMed     Text format     Abstract available


  18. SUD A, Thomsen H, Sundquist K, Houlston RS, et al
    Risk of Second Cancer in Hodgkin Lymphoma Survivors and Influence of Family History.
    J Clin Oncol. 2017 Mar 13:JCO2016709709. doi: 10.1200/JCO.2016.70.9709.
    PubMed     Text format     Abstract available


    February 2017
  19. BROCKELMANN PJ, Goergen H, Kohnhorst C, von Tresckow B, et al
    Late Relapse of Classical Hodgkin Lymphoma: An Analysis of the German Hodgkin Study Group HD7 to HD12 Trials.
    J Clin Oncol. 2017 Feb 27:JCO2016713289. doi: 10.1200/JCO.2016.71.3289.
    PubMed     Text format     Abstract available


    January 2017
  20. ADAMS HJ, Kwee TC
    Predictive Value of Interim [18F]Fluorodeoxyglucose-Positron Emission Tomography in Advanced-Stage Hodgkin Lymphoma Is Not Well Established.
    J Clin Oncol. 2017;35:370-371.
    PubMed     Text format    


  21. HESS CF, Schirmer MA
    How Relevant Is Treatment-Related Infertility for Individual Treatment Selection in Hodgkin Lymphoma?
    J Clin Oncol. 2017;35:372.
    PubMed     Text format    


  22. HAWKES EA, Chong G, Grigg A
    Is Upfront Escalated BEACOPP for Advanced Hodgkin Lymphoma Becoming a Distant Memory?
    J Clin Oncol. 2017;35:371-372.
    PubMed     Text format    


  23. JAKOBSEN LH, Bogsted M, Brown PN, Arboe B, et al
    Minimal Loss of Lifetime for Patients With Diffuse Large B-Cell Lymphoma in Remission and Event Free 24 Months After Treatment: A Danish Population-Based Study.
    J Clin Oncol. 2017 Jan 17:JCO2016700765. doi: 10.1200/JCO.2016.70.0765.
    PubMed     Text format     Abstract available


  24. DAVIDS MS, Roberts AW, Seymour JF, Pagel JM, et al
    Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma.
    J Clin Oncol. 2017 Jan 17:JCO2016704320. doi: 10.1200/JCO.2016.70.4320.
    PubMed     Text format     Abstract available


  25. GIBSON CJ, Lindsley RC, Tchekmedyian V, Mar BG, et al
    Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma.
    J Clin Oncol. 2017 Jan 9:JCO2016716712.
    PubMed     Text format     Abstract available


  26. YAMAGUCHI M, Suzuki R, Oguchi M, Asano N, et al
    Treatments and Outcomes of Patients With Extranodal Natural Killer/T-Cell Lymphoma Diagnosed Between 2000 and 2013: A Cooperative Study in Japan.
    J Clin Oncol. 2017;35:32-39.
    PubMed     Text format     Abstract available


    December 2016
  27. VAN IMHOFF GW, McMillan A, Matasar MJ, Radford J, et al
    Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The ORCHARRD Study.
    J Clin Oncol. 2016 Dec 28:JCO2016690198.
    PubMed     Text format     Abstract available


  28. LAFFON E, Marthan R
    On the Cutoff of Baseline Total Metabolic Tumor Volume in High-Tumor-Burden Follicular Lymphoma.
    J Clin Oncol. 2016 Dec 28:JCO2016706150.
    PubMed     Text format    


  29. ADAMS HJ, Kwee TC
    Overestimated Value of Baseline Total Metabolic Tumor Volume at 18F-Labeled Fluorodeoxyglucose Positron Emission Tomography in Follicular Lymphoma.
    J Clin Oncol. 2016 Dec 28:JCO2016704890.
    PubMed     Text format    


  30. SHI Q, Flowers CR, Hiddemann W, Marcus R, et al
    Thirty-Month Complete Response as a Surrogate End Point in First-Line Follicular Lymphoma Therapy: An Individual Patient-Level Analysis of Multiple Randomized Trials.
    J Clin Oncol. 2016 Dec 28:JCO2016708651.
    PubMed     Text format     Abstract available


  31. BEHRINGER K, Goergen H, Muller H, Thielen I, et al
    Cancer-Related Fatigue in Patients With and Survivors of Hodgkin Lymphoma: The Impact on Treatment Outcome and Social Reintegration.
    J Clin Oncol. 2016;34:4329-4337.
    PubMed     Text format     Abstract available


  32. MEHTA-SHAH N, Horwitz SM
    Lenalidomide in Adult T-Cell Leukemia/Lymphoma.
    J Clin Oncol. 2016;34:4066-4067.
    PubMed     Text format    


    September 2016
  33. ISHIDA T, Fujiwara H, Nosaka K, Taira N, et al
    Multicenter Phase II Study of Lenalidomide in Relapsed or Recurrent Adult T-Cell Leukemia/Lymphoma: ATLL-002.
    J Clin Oncol. 2016 Sep 12. pii: JCO677732.
    PubMed     Text format     Abstract available


  34. SCHODER H, Moskowitz C
    Metabolic Tumor Volume in Lymphoma: Hype or Hope?
    J Clin Oncol. 2016 Sep 6. pii: JCO693747.
    PubMed     Text format    


    August 2016
  35. MEIGNAN M, Cottereau AS, Versari A, Chartier L, et al
    Baseline Metabolic Tumor Volume Predicts Outcome in High-Tumor-Burden Follicular Lymphoma: A Pooled Analysis of Three Multicenter Studies.
    J Clin Oncol. 2016 Aug 22. pii: JCO669440.
    PubMed     Text format     Abstract available


  36. VASSILAKOPOULOS TP, Johnson PW
    HD2000 Update in Hodgkin Lymphoma-ABVD or BEACOPP?
    J Clin Oncol. 2016 Aug 15. pii: JCO679431.
    PubMed     Text format    


  37. YANIK EL, Achenbach CJ, Gopal S, Coghill AE, et al
    Changes in Clinical Context for Kaposi's Sarcoma and Non-Hodgkin Lymphoma Among People With HIV Infection in the United States.
    J Clin Oncol. 2016 Aug 9. pii: JCO676999.
    PubMed     Text format     Abstract available


  38. FUJI S, Inoue Y, Utsunomiya A, Moriuchi Y, et al
    Pretransplantation Anti-CCR4 Antibody Mogamulizumab Against Adult T-Cell Leukemia/Lymphoma Is Associated With Significantly Increased Risks of Severe and Corticosteroid-Refractory Graft-Versus-Host Disease, Nonrelapse Mortality, and Overall Mortality.
    J Clin Oncol. 2016 Aug 9. pii: JCO678250.
    PubMed     Text format     Abstract available


    July 2016
  39. STEPHENS DM, Li H, LeBlanc ML, Puvvada SD, et al
    Continued Risk of Relapse Independent of Treatment Modality in Limited-Stage Diffuse Large B-Cell Lymphoma: Final and Long-Term Analysis of Southwest Oncology Group Study S8736.
    J Clin Oncol. 2016 Jul 5. pii: JCO654582.
    PubMed     Text format     Abstract available


  40. SCHMITZ N, Zeynalova S, Nickelsen M, Kansara R, et al
    CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP.
    J Clin Oncol. 2016 Jul 5. pii: JCO656520.
    PubMed     Text format     Abstract available


  41. SANTORO A, Mazza R, Pulsoni A, Re A, et al
    Bendamustine in Combination With Gemcitabine and Vinorelbine Is an Effective Regimen As Induction Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma: Final Results of a Multicenter Phase II Study.
    J Clin Oncol. 2016 Jul 5. pii: JCO664466.
    PubMed     Text format     Abstract available


    June 2016
  42. ARMAND P, Shipp MA, Ribrag V, Michot JM, et al
    Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure.
    J Clin Oncol. 2016 Jun 27. pii: JCO673467.
    PubMed     Text format     Abstract available


  43. SARKOZY C, Trneny M, Xerri L, Wickham N, et al
    Risk Factors and Outcomes for Patients With Follicular Lymphoma Who Had Histologic Transformation After Response to First-Line Immunochemotherapy in the PRIMA Trial.
    J Clin Oncol. 2016 Jun 13. pii: JCO657163.
    PubMed     Text format     Abstract available


  44. LINK BK
    Will a Better Understanding of the Problem With Transformed Follicular Lymphoma Lead to Better Outcomes?
    J Clin Oncol. 2016 Jun 13. pii: JCO674234.
    PubMed     Text format    


  45. HAPGOOD G, Zheng Y, Sehn LH, Villa D, et al
    Evaluation of the Risk of Relapse in Classical Hodgkin Lymphoma at Event-Free Survival Time Points and Survival Comparison With the General Population in British Columbia.
    J Clin Oncol. 2016 Jun 6. pii: JCO654194.
    PubMed     Text format     Abstract available


    May 2016
  46. DEMEESTERE I, Brice P, Peccatori FA, Kentos A, et al
    No Evidence for the Benefit of Gonadotropin-Releasing Hormone Agonist in Preserving Ovarian Function and Fertility in Lymphoma Survivors Treated With Chemotherapy: Final Long-Term Report of a Prospective Randomized Trial.
    J Clin Oncol. 2016 May 23. pii: JCO658864.
    PubMed     Text format     Abstract available


  47. CRUMP M, Leppa S, Fayad L, Lee JJ, et al
    Randomized, Double-Blind, Phase III Trial of Enzastaurin Versus Placebo in Patients Achieving Remission After First-Line Therapy for High-Risk Diffuse Large B-Cell Lymphoma.
    J Clin Oncol. 2016 May 23. pii: JCO657171.
    PubMed     Text format     Abstract available


  48. APPEL BE, Chen L, Buxton AB, Hutchison RE, et al
    Minimal Treatment of Low-Risk, Pediatric Lymphocyte-Predominant Hodgkin Lymphoma: A Report From the Children's Oncology Group.
    J Clin Oncol. 2016 May 16. pii: JCO653469.
    PubMed     Text format     Abstract available


  49. VORDERMARK D, Pelz T
    Coronary Heart Disease After Mediastinal Radiotherapy for Hodgkin Lymphoma: Can Risk Calculations From Historic Cohorts Be Used Today?
    J Clin Oncol. 2016 May 2. pii: JCO658286.
    PubMed     Text format    


  50. MAZZOLA R, Giaj Levra N, Alongi F
    Radiation Dose-Response Relationship for Risk of Coronary Heart Disease in Survivors of Hodgkin Lymphoma.
    J Clin Oncol. 2016 May 2. pii: JCO667840.
    PubMed     Text format    


    April 2016
  51. CARDE P, Karrasch M, Fortpied C, Brice P, et al
    Eight Cycles of ABVD Versus Four Cycles of BEACOPPescalated Plus Four Cycles of BEACOPPbaseline in Stage III to IV, International Prognostic Score >/= 3, High-Risk Hodgkin Lymphoma: First Results of the Phase III EORTC 20012 Intergroup Trial.
    J Clin Oncol. 2016 Apr 25. pii: JCO645648.
    PubMed     Text format     Abstract available


  52. ROEMER MG, Advani RH, Ligon AH, Natkunam Y, et al
    PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome.
    J Clin Oncol. 2016 Apr 11. pii: JCO664482.
    PubMed     Text format     Abstract available


  53. PRESS OW, Li H, Schoder H, Straus DJ, et al
    US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816.
    J Clin Oncol. 2016 Apr 11. pii: JCO631119.
    PubMed     Text format     Abstract available


  54. BORCHMANN P, Engert A
    Balancing the Risk-Benefit Ratio in the Treatment of Patients With Advanced-Stage Hodgkin Lymphoma.
    J Clin Oncol. 2016 Apr 11. pii: JCO663823.
    PubMed     Text format    


    March 2016
  55. GLASS J, Won M, Schultz CJ, Brat D, et al
    Phase I and II Study of Induction Chemotherapy With Methotrexate, Rituximab, and Temozolomide, Followed By Whole-Brain Radiotherapy and Postirradiation Temozolomide for Primary CNS Lymphoma: NRG Oncology RTOG 0227.
    J Clin Oncol. 2016 Mar 28. pii: JCO648634.
    PubMed     Text format     Abstract available


  56. ADAMS SV, Newcomb PA, Shustov AR
    Racial Patterns of Peripheral T-Cell Lymphoma Incidence and Survival in the United States.
    J Clin Oncol. 2016;34:963-71.
    PubMed     Text format     Abstract available


  57. DAL PRA A, Berlin A, Kumareswaran R, Schattner AJ, et al
    Liver Failure After Abdominal Irradiation: Identifying the Right Suspects.
    J Clin Oncol. 2016;34:e80-3.
    PubMed     Text format    


  58. KORFEL A, Schlegel U, Herrlinger U, Dreyling M, et al
    Phase II Trial of Temsirolimus for Relapsed/Refractory Primary CNS Lymphoma.
    J Clin Oncol. 2016 Mar 14. pii: JCO649897.
    PubMed     Text format     Abstract available


  59. MAMOT C
    Reply to H.J.A. Adams and T.C. Kwee.
    J Clin Oncol. 2016;34:766-7.
    PubMed     Text format    


    February 2016
  60. HOSTER E, Rosenwald A, Berger F, Bernd HW, et al
    Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma Network.
    J Clin Oncol. 2016 Feb 29. pii: JCO638387.
    PubMed     Text format     Abstract available


  61. NG AK, Dabaja BS, Hoppe RT, Illidge T, et al
    Re-Examining the Role of Radiation Therapy for Diffuse Large B-Cell Lymphoma in the Modern Era.
    J Clin Oncol. 2016 Feb 22. pii: JCO649418.
    PubMed     Text format    


  62. SMITS NC, Sentman CL
    Bispecific T-Cell Engagers (BiTEs) as Treatment of B-Cell Lymphoma.
    J Clin Oncol. 2016 Feb 16. pii: JCO649970.
    PubMed     Text format    


  63. GOEBELER ME, Knop S, Viardot A, Kufer P, et al
    Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study.
    J Clin Oncol. 2016 Feb 16. pii: JCO591586.
    PubMed     Text format     Abstract available


  64. ZINZANI PL, Broccoli A, Gioia DM, Castagnoli A, et al
    Interim Positron Emission Tomography Response-Adapted Therapy in Advanced-Stage Hodgkin Lymphoma: Final Results of the Phase II Part of the HD0801 Study.
    J Clin Oncol. 2016 Feb 16. pii: JCO630699.
    PubMed     Text format     Abstract available


  65. ABRAMSON JS, Ferry JA, Muse VV, Lanuti M, et al
    Extranodal Marginal Zone Lymphoma Presenting As Miliary Lung Disease.
    J Clin Oncol. 2016;34:e27-30.
    PubMed     Text format    


    January 2016
  66. ADAMS SV, Newcomb PA, Shustov AR
    Racial Patterns of Peripheral T-Cell Lymphoma Incidence and Survival in the United States.
    J Clin Oncol. 2016 Jan 25. pii: JCO635540.
    PubMed     Text format     Abstract available


  67. TOWNS JN, Dripps L, Jenkins S, Lackore K, et al
    Impact of lymphoma survivorship clinic visit on patient-centered outcomes.
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available


  68. SAUNDERS T, Burns R, Nyce J, Wendell K, et al
    Health-related quality of life (HRQL) in Hodgkin lymphoma (HL): A systematic review (SR).
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available


  69. BIRD BR, Cahill M, Murphy CG, O'Reilly S, et al
    Assessing the quality of life of non-Hodgkin lymphoma survivors: A population-based study.
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available


  70. WU YL, Garcia Delgadillo J, Munoz-Plaza CE
    Use of recommended post-treatment services for adolescent and young adult Hodgkin lymphoma survivors.
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available


  71. VEER MV, Aleman BM, Dekker N, Raemaekers JM, et al
    A Dutch nationwide survivorship care program for Hodgkin lymphoma survivors.
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available


  72. CHEAH CY, Seymour JF, Wang ML
    Mantle Cell Lymphoma.
    J Clin Oncol. 2016 Jan 11. pii: JCO635904.
    PubMed     Text format     Abstract available


  73. ADAMS HJ, Kwee TC
    Both Interim and End-of-Treatment 18F-Fluoro-2-Deoxy-d-Glucose Positron Emission Tomography Scans Have Low Value in Diffuse Large B-Cell Lymphoma.
    J Clin Oncol. 2016 Jan 11. pii: JCO637728.
    PubMed     Text format    


    December 2015
  74. TAVERNA C, Martinelli G, Hitz F, Mingrone W, et al
    Rituximab Maintenance for a Maximum of 5 Years After Single-Agent Rituximab Induction in Follicular Lymphoma: Results of the Randomized Controlled Phase III Trial SAKK 35/03.
    J Clin Oncol. 2015 Dec 28. pii: JCO613968.
    PubMed     Text format     Abstract available


  75. ENGERT A
    ABVD or BEACOPP for Advanced Hodgkin Lymphoma.
    J Clin Oncol. 2015 Dec 28. pii: JCO648683.
    PubMed     Text format    


  76. MERLI F, Luminari S, Gobbi PG, Cascavilla N, et al
    Long-Term Results of the HD2000 Trial Comparing ABVD Versus BEACOPP Versus COPP-EBV-CAD in Untreated Patients With Advanced Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi.
    J Clin Oncol. 2015 Dec 28. pii: JCO624817.
    PubMed     Text format     Abstract available


  77. ASSELIN BL, Devidas M, Chen L, Franco VI, et al
    Cardioprotection and Safety of Dexrazoxane in Patients Treated for Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Advanced-Stage Lymphoblastic Non-Hodgkin Lymphoma: A Report of the Children's Oncology Group Randomized Trial Pediatric Oncology
    J Clin Oncol. 2015 Dec 23. pii: JCO608851.
    PubMed     Text format     Abstract available


  78. O'DWYER KM, Advani AS
    When to Treat Adults Like Children: Optimizing Therapy for Lymphoblastic Lymphoma in Young Adults.
    J Clin Oncol. 2015 Dec 23. pii: JCO647156.
    PubMed     Text format     Abstract available


  79. WEIBULL CE, Eloranta S, Smedby KE, Bjorkholm M, et al
    Pregnancy and the Risk of Relapse in Patients Diagnosed With Hodgkin Lymphoma.
    J Clin Oncol. 2015 Dec 14. pii: JCO633446.
    PubMed     Text format     Abstract available


  80. LEPRETRE S, Touzart A, Vermeulin T, Picquenot JM, et al
    Pediatric-Like Acute Lymphoblastic Leukemia Therapy in Adults With Lymphoblastic Lymphoma: The GRAALL-LYSA LL03 Study.
    J Clin Oncol. 2015 Dec 7. pii: JCO615385.
    PubMed     Text format     Abstract available


  81. ARMITAGE JO, Vose JM
    To Surveil or Not to Surveil.
    J Clin Oncol. 2015;33:3983-4.
    PubMed     Text format    


  82. BARRINGTON SF, Mikhaeel NG, Kostakoglu L, Meignan M, et al
    Reply to G. Keramida et al.
    J Clin Oncol. 2015;33:4121-2.
    PubMed     Text format    


    November 2015
  83. MARALDO MV, Ng AK
    Minimizing Cardiac Risks With Contemporary Radiation Therapy for Hodgkin Lymphoma.
    J Clin Oncol. 2015 Nov 30. pii: JCO646588.
    PubMed     Text format    


  84. CLEMENS MW, Medeiros LJ, Butler CE, Hunt KK, et al
    Complete Surgical Excision Is Essential for the Management of Patients With Breast Implant-Associated Anaplastic Large-Cell Lymphoma.
    J Clin Oncol. 2015 Nov 30. pii: JCO633412.
    PubMed     Text format     Abstract available


  85. VAN NIMWEGEN FA, Schaapveld M, Cutter DJ, Janus CP, et al
    Radiation Dose-Response Relationship for Risk of Coronary Heart Disease in Survivors of Hodgkin Lymphoma.
    J Clin Oncol. 2015 Nov 16. pii: JCO.2015.63.4444.
    PubMed     Text format     Abstract available


  86. KIM YH, Tavallaee M, Sundram U, Salva KA, et al
    Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sezary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project.
    J Clin Oncol. 2015;33:3750-8.
    PubMed     Text format     Abstract available


    October 2015
  87. NOWAKOWSKI GS, Macon WR, Gascoyne RD, Witzig TE, et al
    Reply to M. Gleeson et al.
    J Clin Oncol. 2015;33:3216-7.
    PubMed     Text format    


    September 2015
  88. KAYE EC
    Pieces of Grief.
    J Clin Oncol. 2015;33:2923-4.
    PubMed     Text format    


    August 2015
  89. CHOW EJ, Asselin BL, Schwartz CL, Doody DR, et al
    Late Mortality After Dexrazoxane Treatment: A Report From the Children's Oncology Group.
    J Clin Oncol. 2015;33:2639-45.
    PubMed     Text format     Abstract available


  90. KREMER LC, van Dalen EC
    Dexrazoxane in Children With Cancer: From Evidence to Practice.
    J Clin Oncol. 2015;33:2594-6.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Malignant Lymphoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: